Seems the structure of the raw Tesamorelin molecule has a hydophillic aspect that makes it prone to clumping in colder solution ... this overview by Jim [HPT Homopetides Telegram]
https://t.me/c/2966968184/8787
outlines the issue "
Tesamorelin has been through three FDA approved formulations over the last 15 years, and the storage requirements tell you everything you need to know.
The original formulation was approved in 2010. Pharmaceutical grade, no stabilizers, and the label said reconstitute and inject immediately because it couldn't sit in solution for a single day.
Then in 2018, EGRIFTA SV came out at a higher concentration and the instructions were the same. Do not store it. Do not refrigerate.
So that's two formulations across eight years, and neither one could be stored after reconstitution.
Then in 2025, they finally solved it by engineering 145 milligrams of a stabilizer into the formulation that wraps around the hydrophobic parts of the molecule and keeps them from clumping together.
And with that, the FDA approved a seven day shelf life for the first time.
At room temperature, still not refrigerated.
The problem is the molecule, not the formulation. Tesamorelin has a synthetic modification on the front end that repels water and the amino acid sequence itself is loaded with hydrophobic residues.
When the temperature drops, those regions on adjacent molecules start binding to each other and that causes gelling.
Those properties are built into the amino acid sequence and exist in every vial of tesamorelin on the planet, regardless of who made it.
The FDA version has a stabilizer engineered to manage that problem. Research grade does not. " ...
HTH